FDA Extends Continuous Marketing Application Pilot 2 Deadline Again
This article was originally published in Pharmaceutical Approvals Monthly
FDA extends continuous marketing application Pilot 2 deadline again. At least eight CDER divisions have chosen INDs for the fast-track pilot program, with eight remaining. Applications will be accepted until Dec. 31
You may also be interested in...
Neurochem Fibrillex misses endpoint
Neurochem's amyloid A amyloidosis agent Fibrillex fails to meet its primary endpoint in a Phase II/III trial, the firm says April 18. Preliminary results from the two-year, 183-patient study found there were 13.4% more patients on Fibrillex than placebo who remained stable or improved (p=0.06). The primary endpoint required a 20% absolute difference in the number of stabilized/improved patients versus placebo (p<0.01). Neurochem, which previously projected a 2005 NDA submission, says it remains committed to Fibrillex and will discuss its complete Phase II/III findings with FDA. Fibrillex was accepted into FDA's continuous marketing application Pilot 2 program by the cardio-renal division in July 2004 (1Pharmaceutical Approvals Monthly December 2004, p. 17)...
HGS Lymphostat-B Is 1 Of 7 Agents Selected For FDA’s Pilot 2 CMA Program
FDA has selected Human Genome Sciences’ lupus biologic Lymphostat-B for the continuous marketing application (CMA) Pilot 2 program, HGS announced March 4.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011